VEGFA and hepatocellular carcinoma: Moreover, according to the results of the phase III trials REACH and REACH‐II, ramucirumab (an anti‐VEGF antibody) has been approved for patients with unresectable HCC with AFP ≥ 400 ng/dL who experience sorafenib failure 143, 144.